Evidence map›Paper›PMID 20956983›Full record

ReviewNature reviews. Clinical oncology2011

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Paula Cramer, Michael Hallek

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Greek Consensus on Chronic Lymphocytic Leukemia (CLL) Treatment.Mediterranean journal of hematology and infectious diseases · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Yoga, immunity and COVID-19: A scoping review.Journal of family medicine and primary care · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Optimizing Treatment of Chronic Lymphocytic Leukemia.Journal of the advanced practitioner in oncology · 2021
    Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Paula CramerDepartment of Internal Medicine I, Center for Integrated Oncology Köln-Bonn, University of Cologne, Germany.
Michael Hallek

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Of all leukemias, chronic lymphocytic leukemia (CLL) shows the highest variability in its clinical presentation and course. CLL can present as an aggressive and life threatening leukemia or as an indolent form that will not require treatment over decades. The currently available clinical staging systems for CLL are simple and inexpensive but lack accuracy to predict disease progression and survival on an individual basis. The increased understanding of the key events of molecular pathogenesis has provided a plethora of novel molecular and biological factors that correlate with the outcome of CLL. This Review provides a concise discussion of the most important discoveries and gives guidance on how to implement novel prognostic tools in the clinical management of CLL by applying the criteria of evidence, relevance, and simplicity to the selection of prognostic markers.

Indexed as

Antineoplastic AgentsBiomarkers, TumorDisease ProgressionHumansLeukemia, Lymphocytic, Chronic, B-CellPrognosisAntineoplastic AgentsBiomarkers, Tumor

Identifiers

PMID20956983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.